🔴 Pacific Biosciences is trading 5.5% down in pre-market after CFO transition and narrower 2026 guidance

Pacific Biosciences is trading $2.41, down 5.49%, following its Q3 report and CFO transition announcement; the exact driver of the pre-market decline is unconfirmed.

• Q3 revenue was $40.6 million, above estimates, and earnings also beat estimates; full-year 2026 revenue guidance narrowed to $155 million–$160 million.
• CFO Jim Gibson stepped down, and the CEO became interim CFO.
• Biotech shares rose 2.08% pre-market, unlike Pacific Biosciences; no reliable volume figure was available.